Reference Range Problem and Functional Deficiency (2026-04-21)

This section covers the systematic gap between population-derived laboratory reference intervals and the thresholds required for optimal cellular function in chronically ill individuals. Evidence spans iron, magnesium, vitamin B12, vitamin D, and thyroid hormones.

1 Vaucher et al. 2012 — Iron Supplementation in Nonanemic Women with Low Ferritin (RCT)

Full Citation:: Vaucher P, Druais PL, Waldvogel S, Favrat B. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ. 2012;184(11):1247–54. DOI:: 10.1503/cmaj.110950 PMID:: 22777991 Study Design:: Multicentre parallel RCT, 44 primary care practices, France; observer-blinded Sample Size:: n=198 (102 iron, 96 placebo), ages 18–53 Ferritin Cutoff:: <50 µg/L with normal hemoglobin (>12.0 g/dL) Key Findings::

- Ferrous sulfate 80 mg elemental iron daily × 12 weeks reduced fatigue score 47.7% vs 28.8% placebo (p=0.02)
- No significant improvement in quality of life, depression, or anxiety
- Iron therapy raised hemoglobin, raised ferritin, reduced soluble transferrin receptor

Reference Range Problem:: WHO iron deficiency threshold is <15 µg/L; most clinical labs flag deficiency only below 12–15 µg/L. This RCT demonstrates fatigue benefit at ferritin levels up to 50 µg/L — more than 3× the WHO cutoff. Patients with ferritin 16–49 µg/L would typically be told their iron is “normal.” Certainty Assessment::

- *Quality:* High — CMAJ, peer-reviewed RCT, independent
- *Sample:* n=198, female only, France primary care
- *Replication:* Supported by Krayenbuehl 2011 and Yokoi 2017 meta-analysis
- *Limitations:* Women only; no ME/CFS patients; short follow-up (12 weeks); no objective performance measures improved

2 Krayenbuehl et al. 2011 — Intravenous Iron for Fatigue in Nonanemic Women (RCT)

Full Citation:: Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. 2011;118(12):3222–7. DOI:: 10.1182/blood-2011-04-346304 PMID:: 21705493 Study Design:: Randomized, double-blind, placebo-controlled trial Sample Size:: n=90 premenopausal women; ferritin ≤50 ng/mL; hemoglobin ≥120 g/L Key Findings::

- In subgroup with ferritin ≤15 ng/mL: fatigue decreased 1.8 (iron) vs 0.4 (placebo), p=0.005
- 82% vs 47% reported subjective improvement in that subgroup (p=0.03)
- Full cohort (up to 50 ng/mL) showed smaller overall effect
- Adverse events 21% iron group vs 7% placebo

Reference Range Problem:: Enrollment threshold of ≤50 ng/mL is well above standard lab deficiency cutoffs (typically 12 ng/mL for women). Strongest benefit was in the ≤15 ng/mL subgroup, confirming functional importance of the near-deficient range that most labs classify as “normal.” Certainty Assessment::

- *Quality:* High — *Blood* journal, double-blind RCT
- *Sample:* n=90, women only
- *Replication:* Consistent with Vaucher 2012
- *Limitations:* Subgroup analysis for main effect; women only; single centre

3 Yokoi and Konomi 2017 — Meta-Analysis of IDWA and Fatigue

Full Citation:: Yokoi K, Konomi A. Iron deficiency without anemia is a potential cause of fatigue: meta-analyses of randomized controlled trials and cross-sectional studies. British Journal of Nutrition. 2017;117(10):1422–31. DOI:: 10.1017/S0007114517001349 PMID:: 28625177 Study Design:: Systematic review + two meta-analyses (6 RCTs, 6 cross-sectional studies) Key Findings::

- RCT pool: iron supplementation significantly reduced fatigue in IDWA (effect size 0.33, p\<0.0001)
- Cross-sectional pool: IDWA status did not significantly predict fatigue (effect size 0.10, p=0.362)
- Interpretation: supplementation improves fatigue; cross-sectional IDWA status alone does not reliably stratify fatigued from non-fatigued individuals

Reference Range Problem:: Ferritin thresholds defining IDWA in included studies ranged from <12 to <50 µg/L across different research teams, confirming there is no consensus on where “normal” iron stores end and functional deficiency begins. Certainty Assessment::

- *Quality:* Medium-high — *British Journal of Nutrition*, systematic methods
- *Sample:* Pooled from 12 studies
- *Replication:* Summarizes existing evidence
- *Limitations:* Heterogeneous ferritin cutoffs; no ME/CFS-specific data; publication bias possible

4 Al-Naseem et al. 2021 — Iron Deficiency Without Anaemia: A Diagnosis That Matters

Full Citation:: Al-Naseem A, Sallam A, Choudhury S, Thachil J. Iron deficiency without anemia: a diagnosis that matters. Clinical Medicine (London). 2021;21(2):107–113. DOI:: 10.7861/clinmed.2020-0582 PMID:: 33762368 Study Design:: Narrative review Key Findings::

- IDWA is at least twice as common as iron deficiency anemia, yet remains clinically underrecognized
- WHO cutoff (\<15 µg/L) misses many clinically significant cases; \<30 µg/L has high specificity and sensitivity for absent bone marrow iron stores
- In inflammatory conditions (relevant to ME/CFS): threshold rises to 100 µg/L (with TSAT \<20% as confirmatory marker)
- Calls for IDWA to be recognized as a standalone clinical diagnosis

Certainty Assessment::

- *Quality:* Medium — *Clinical Medicine* (Royal College of Physicians), peer-reviewed narrative review
- *Sample:* Review, no primary data
- *Limitations:* Narrative review; no ME/CFS data; practical guidance for general medicine

5 Workinger et al. 2018 — Challenges in the Diagnosis of Magnesium Status

Full Citation:: Workinger JL, Doyle RP, Bortz J. Challenges in the diagnosis of magnesium status. Nutrients. 2018;10(9):1202. DOI:: 10.3390/nu10091202 PMID:: 30200431 Study Design:: Narrative review Key Findings::

- Only ~1% of total body magnesium is in blood; 99% is intracellular (53% bone, 27% muscle, 19% other tissues)
- Standard serum magnesium assay has "no reliable correlation" with total body or tissue magnesium levels
- Serum levels are tightly regulated by renal excretion and remain "normal" even when total body stores are depleted
- No validated rapid bedside test for true magnesium status exists
- RBC magnesium is a better (but imperfect and non-standardized) proxy
- Estimated 45% of Americans are magnesium-deficient by dietary intake measures despite frequently normal serum results

Reference Range Problem:: The standard serum magnesium reference interval measures the wrong compartment for chronic deficiency detection. Patients with textbook magnesium deficiency symptoms (fatigue, muscle cramps, sleep disruption) routinely present with “normal” serum magnesium because the body preserves serum levels at the expense of tissue stores. Certainty Assessment::

- *Quality:* Medium — *Nutrients* (MDPI), MEDLINE-indexed, systematic narrative methods
- *Sample:* Review, no primary data
- *Limitations:* No primary data; MDPI open-access journal; recommendation to use RBC magnesium is not uniformly endorsed

6 Russell-Jones 2022 — Functional Vitamin B12 Deficiency in Chronic Fatigue Syndrome

Full Citation:: Russell-Jones G. Functional vitamin B12 deficiency in chronic fatigue syndrome. International Journal of Psychiatry. 2022;7(3):153–158. DOI:: 10.33140/IJP (journal prefix; article-level DOI not confirmed in PubMed) PMID:: Not indexed in PubMed Study Design:: Observational comparison, n=350 CFS individuals Key Findings::

- Majority of CFS patients showed functional B12 deficiency markers (elevated methylmalonic acid, urinary metabolites) despite normal to elevated serum B12
- Termed "paradoxical vitamin B12 deficiency" — serum B12 does not reflect functional B12 status
- B2 (riboflavin) co-deficiency proposed as mechanism: riboflavin is required for functional B12 activity
- Serum B12 reference ranges measure circulating cobalamin, not intracellular utilization

Certainty Assessment::

- *Quality:* Low — not PubMed-indexed; Opast Publishing (lower-tier open-access); peer review quality uncertain
- *Sample:* n=350, no control group details confirmed
- *Replication:* Not independently replicated at this level of specificity
- *Limitations:* Low-tier journal; methods not fully validated; treat as hypothesis-generating only; use `speculation` environment

7 Charoenngam and Holick 2020 — Immunologic Effects of Vitamin D

Full Citation:: Charoenngam N, Holick MF. Immunologic effects of vitamin D on human health and disease. Nutrients. 2020;12(7):2097. DOI:: 10.3390/nu12072097 PMID:: 32679784 Study Design:: Narrative review Key Findings::

- Classical bone-health threshold (basis for most lab reference ranges): 20 ng/mL (50 nmol/L)
- Optimal immune function threshold: 40--60 ng/mL (100--150 nmol/L)
- Active vitamin D modulates T-cell and B-cell activity, cathelicidin production, anti-inflammatory cytokines
- Significant inter-individual variation in VDR gene expression: identical serum 25(OH)D levels produce different cellular immune responses

Reference Range Problem:: A 25(OH)D of 22 ng/mL is labeled “sufficient” by standard lab reference ranges (bone health threshold). The immune-optimization threshold is 2–3× higher. VDR polymorphisms mean some individuals may require substantially higher serum levels to achieve equivalent intracellular vitamin D signaling. Certainty Assessment::

- *Quality:* Medium — *Nutrients* (MDPI), MEDLINE-indexed; Holick is leading authority in field
- *Sample:* Review; draws on mechanistic, observational, and RCT data
- *Replication:* Optimal immune threshold supported by multiple independent research groups
- *Limitations:* Narrative review; Holick has disclosed commercial relationships (speaking fees); optimal immune threshold not established by large RCTs; VITAL trial showed partial benefits only

8 Holick et al. 2011 — Endocrine Society Vitamin D Clinical Practice Guideline

Full Citation:: Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2011;96(7):1911–30. DOI:: 10.1210/jc.2011-0385 PMID:: 21646368 Study Design:: Evidence-based clinical practice guideline (Endocrine Society) Key Findings::

- Deficiency defined as \<20 ng/mL; insufficiency 21--29 ng/mL; sufficiency ≥30 ng/mL
- Recommends targeting 40--60 ng/mL for maximum extraskeletal (immune, cancer, cardiovascular) benefit
- Adults at risk may require 1500--2000 IU/day to achieve >30 ng/mL
- The guideline itself makes explicit that bone-health cutoffs and extraskeletal-benefit thresholds are different

Certainty Assessment::

- *Quality:* High — Endocrine Society, evidence-graded guideline, >20,000 citations
- *Replication:* Widely adopted; partially updated by 2024 Endocrine Society guideline
- *Limitations:* 2011 guideline; some extraskeletal benefit claims revised in light of subsequent RCTs (VITAL); Holick COI disclosure

9 Panicker et al. 2009 — DIO2 Polymorphism, Psychological Wellbeing, and T4/T3 Response

Full Citation:: Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM, Dayan CM. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. Journal of Clinical Endocrinology & Metabolism. 2009;94(5):1623–9. DOI:: 10.1210/jc.2008-1301 PMID:: 19190113 Study Design:: Prospective genetic subgroup analysis within the Weston Area T4 T3 Study (WATTS) Sample Size:: n=552 subjects on T4 monotherapy for hypothyroidism Key Findings::

- DIO2 rs225014 CC genotype (present in 16% of the sample) associated with worse baseline psychological wellbeing on T4 alone (GHQ 14.1 vs 12.8, p=0.03)
- CC genotype showed greater benefit from T4+T3 combination therapy: +2.3 GHQ points at 3 months, +1.4 at 12 months (p=0.03 repeated-measures ANOVA)
- Critically: the CC genotype had NO impact on serum TSH, T3, or T4 levels
- DIO2 encodes type II deiodinase, which converts T4 to active T3 intracellularly in brain and pituitary; Thr92Ala substitution reduces enzyme efficiency

Reference Range Problem:: TSH is the primary clinical marker of thyroid function and was completely normal in all genotype groups. Yet 16% of hypothyroid patients had measurably worse psychological function explicable only by impaired intracellular T4-to-T3 conversion — a process serum TSH cannot assess. Tissue-level thyroid hormone deficiency exists in a measurable fraction of patients despite normal serum thyroid function tests. Certainty Assessment::

- *Quality:* High — *JCEM*, prospective genetic analysis, validated study design
- *Sample:* n=552 on T4 therapy (hypothyroid patients, not general population or ME/CFS)
- *Replication:* Mixed; the Thr92Ala DIO2 polymorphism principle is supported by multiple groups; specific effect sizes contested
- *Limitations:* Hypothyroid patients only; not applicable to euthyroid individuals directly; p-values borderline (0.02--0.06); does not apply to TSH screening in general ME/CFS without known hypothyroidism

10 Ruiz-Núñez et al. 2018 — Low T3 Syndrome in ME/CFS (Case-Control)

Full Citation:: Ruiz-Núñez B, Tarasse R, Vogelaar EF, Dijck-Brouwer DAJ, Muskiet FAJ. Higher prevalence of “low T3 syndrome” in patients with chronic fatigue syndrome: a case–control study. Frontiers in Endocrinology. 2018;9:97. DOI:: 10.3389/fendo.2018.00097 PMID:: 29615976 Study Design:: Case-control Sample Size:: n=98 ME/CFS patients; n=99 age/sex-matched healthy controls Key Findings::

- ME/CFS patients showed lower FT3, total T3, total T4; elevated reverse T3 percentage
- FT3 below reference range in 16/98 CFS patients vs 7/99 controls (OR 2.56, p=0.035)
- TSH was normal in all subjects — the abnormality is invisible to TSH-based screening
- Reduced deiodination function and thyroid secretory capacity in CFS group
- Pattern resembles mild non-thyroidal illness syndrome (NTIS), suggesting systemic illness suppresses T4→T3 conversion independently of primary thyroid disease

Reference Range Problem:: Standard thyroid screening uses TSH only. All ME/CFS patients in this study would be classified “euthyroid” by TSH. FT3 and reverse T3 measurements — which revealed a 2.56-fold increased risk of low T3 — are not part of routine thyroid function panels. Certainty Assessment::

- *Quality:* Medium — *Frontiers in Endocrinology* (peer-reviewed open-access; variable review quality)
- *Sample:* n=197 case-control; adequate size
- *Replication:* Not independently replicated in larger ME/CFS cohort
- *Limitations:* Case-control cannot establish causality; Frontiers publication; NTIS pattern may reflect effect rather than cause of ME/CFS

11 Ott et al. 2011 — Hashimoto’s Thyroiditis: Fatigue Independent of TSH

Full Citation:: Ott J, Promberger R, Kober F, Neuhold N, Tea M, Huber JC, Hermann M. Hashimoto’s thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: a prospective case-control study in women undergoing thyroidectomy for benign goiter. Thyroid. 2011;21(2):161–7. DOI:: 10.1089/thy.2010.0191 PMID:: 21186954 Study Design:: Prospective case-control (histology-confirmed Hashimoto’s as case definition) Sample Size:: n=426 euthyroid women undergoing thyroid surgery; 28 (6.6%) confirmed Hashimoto’s on histology Key Findings::

- Anti-TPO cutoff for true thyroid inflammation calculated at 121.0 IU/mL
- Women above cutoff had significantly higher symptom counts (6.7±2.5 vs 4.1±2.8, p\<0.001)
- Chronic fatigue was significantly more prevalent in the Hashimoto's group
- TSH levels were statistically identical between groups (1.7±1.3 vs 1.5±1.4 µU/mL)
- Autoimmune inflammation itself — not hypothyroidism — drives fatigue and other symptoms

Reference Range Problem:: Euthyroid Hashimoto’s patients have “normal” TSH by every standard reference interval. The symptom burden (including chronic fatigue) is driven by TPO antibody-mediated autoimmune activity, which is not part of standard thyroid function panels and has no established reference range for “safe” antibody levels. Certainty Assessment::

- *Quality:* High — *Thyroid* (leading specialty journal), prospective, histology-confirmed case definition
- *Sample:* n=426 total; Hashimoto's subgroup n=28 (small)
- *Replication:* Consistent with wider literature on euthyroid Hashimoto's symptom burden
- *Limitations:* Women only (surgical sample); small Hashimoto's subgroup; surgical sample may overrepresent structural thyroid disease

12 Joustra et al. 2017 — Vitamin and Mineral Status in CFS/Fibromyalgia (Systematic Review)

Full Citation:: Joustra ML, Minovic I, Janssens KAM, Bakker SJL, Rosmalen JGM. Vitamin and mineral status in chronic fatigue syndrome and fibromyalgia syndrome: a systematic review and meta-analysis. PLoS One. 2017;12(4):e0176631. DOI:: 10.1371/journal.pone.0176631 PMID:: 28453534 Study Design:: Systematic review + meta-analysis; 45 studies (5 RCTs, 40 observational) Key Findings::

- No consistent differences in vitamin D, magnesium, B12, iron, zinc, or folate between CFS/FMS patients and controls using standard serum/plasma measures
- Vitamin E lower in patients vs controls, but effect disappeared in higher-quality studies
- Supplementation RCTs showed no consistent clinical improvements
- Study quality was generally poor; substantial heterogeneity
- Conclusion: "Little evidence was found to support the hypothesis that vitamin and mineral deficiencies play a role in the pathophysiology of CFS and FMS"

Critical Interpretation:: This is the necessary empirical counterweight. However, the systematic review used standard serum/plasma assays — precisely the measures identified elsewhere in this section as inadequate for detecting intracellular and functional deficiencies (magnesium, B12) or for applying functional thresholds (ferritin, vitamin D). The negative finding should be read as “standard serum measures show no consistent differences,” not “no functional deficiency exists.” The two conclusions are compatible. Certainty Assessment::

- *Quality:* Medium-high — *PLoS One*, systematic methods, pre-registered
- *Sample:* 45 studies pooled
- *Limitations:* Relies entirely on serum/plasma measures; poor primary study quality; high heterogeneity; may miss functional deficiencies by design; does not address the reference range problem directly